Stock CHARMING SHOPPES, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Charming Shoppes, Inc.

Equities

US1611331034

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Charming Shoppes, Inc.

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Coherus BioSciences Management to Present at 36th NASDAQ OMX Investor Program 
GL
Coherus BioSciences Prevails in ‘135 IPR Decision
GL
Coherus BioSciences Reports First Quarter 2017 Corporate Highlights and Financial Results
GL
Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in May
GL
Coherus BioSciences Completes Patent Dance Exchange with Amgen for Neulasta Biosimilar
GL
Coherus BioSciences to Report First Quarter 2017 Financial Results on May 8th
GL
Coherus BioSciences Appoints Erik Wiberg as Executive Vice President of Corporate Development
GL
Coherus BioSciences Reports Fourth Quarter and Full Year 2016 Corporate Highlights and Financial Results
GL
Coherus Addresses Trade Secret Action Filed by Amgen
GL
Statement by Coherus CEO Regarding Biosimilars User Fees
GL
Coherus Announces CHS-1420 Pharmacokinetic Clinical Bioequivalence Study Meets Primary Endpoint
GL
Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in March
GL
Coherus BioSciences to Report Fourth Quarter and Full Year 2016 Financial Results on March 13th
GL
Coherus BioSciences Announces New Employment Inducement Grants
GL
Coherus Prices Public Offering of Common Stock
GL
Coherus Announces Proposed Public Offering of Common Stock
GL
Coherus BioSciences Files Four Petitions for Inter Partes Review Against AbbVie’s HUMIRA® Formulation Patent 9,085,619
GL
Charming Shoppes : Coherus BioSciences Announces Positive Topline 24-Week Treatment Phase Three Results for CHS-1420 (HUMIRA® Biosimilar Candidate) in Patients with Psoriasis
PU
Coherus BioSciences Announces Positive Topline 24-Week Treatment Phase Three Results for CHS-1420 (HUMIRA® Biosimilar Candidate) in Patients with Psoriasis
GL
Coherus BioSciences Management to Present at The 35th Annual J.P. Morgan Healthcare Conference
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Charming Shoppes, Inc.